TD Waterhouse Canada Inc. Purchases 9,585 Shares of Boston Scientific Corporation $BSX

TD Waterhouse Canada Inc. increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 7.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 130,390 shares of the medical equipment provider’s stock after acquiring an additional 9,585 shares during the period. TD Waterhouse Canada Inc.’s holdings in Boston Scientific were worth $12,477,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of BSX. Steph & Co. acquired a new stake in Boston Scientific during the 3rd quarter worth approximately $25,000. Financial Consulate Inc. bought a new position in shares of Boston Scientific during the third quarter valued at $25,000. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the second quarter worth $26,000. Sound Income Strategies LLC grew its stake in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares during the last quarter. Finally, Kilter Group LLC acquired a new stake in Boston Scientific in the second quarter valued at $30,000. 89.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on BSX. Truist Financial cut their target price on Boston Scientific from $130.00 to $120.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. UBS Group reaffirmed a “buy” rating on shares of Boston Scientific in a research note on Wednesday, December 17th. Evercore ISI set a $112.00 target price on Boston Scientific in a report on Monday, January 5th. Morgan Stanley raised their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Finally, TD Cowen reaffirmed a “buy” rating on shares of Boston Scientific in a research note on Thursday, December 11th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $123.89.

Boston Scientific Stock Down 1.6%

Boston Scientific stock opened at $92.26 on Friday. The company has a market capitalization of $136.78 billion, a PE ratio of 49.34, a PEG ratio of 1.66 and a beta of 0.67. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50. The firm’s fifty day moving average is $95.27 and its 200 day moving average is $99.60. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47.

Insider Activity

In other news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This represents a 34.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 80,204 shares of company stock worth $7,998,563. Company insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.